Its levels have been found to be reduced in patients with NAFLD/MASLD and obesity, with data suggesting that hepatic insulin resistance may influence IGF-I levels through modulation of growth hormone-stimulated hepatic synthesis of IGF-I [37,60]. Here, IGF1 is linked to obesity disorder.